Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.77) by 22.02 percent. This is a 67.69 percent increase over losses of $(9.10) per share from the same period last year. The company reported quarterly sales of $14.523 million which beat the analyst consensus estimate of $8.079 million by 79.75 percent. This is a 16.53 percent decrease over sales of $17.399 million the same period last year.